1. Urotensin II receptor expression in patients with ulcerative colitis: a pilot study
- Author
-
Stefania Lama, Francesco Luzza, Francesco Merlino, Marcello Dallio, Michele Caraglia, Paolo Grieco, Paola Stiuso, Alessandro Federico, Concetta Tuccillo, Antonietta Gerarda Gravina, Carmelina Loguercio, Marco Martorano, Ludovico Abenavoli, Gravina, Antonietta G, Dallio, Marcello, Tuccillo, Concetta, Martorano, Marco, Abenavoli, Ludovico, Luzza, Francesco, Stiuso, Paola, Lama, Stefania, Grieco, Paolo, Merlino, Francesco, Caraglia, Michele, Loguercio, Carmelina, and Federico, Alessandro
- Subjects
Adult ,Male ,Untranslated region ,medicine.medical_specialty ,Colorectal cancer ,Endocrinology, Diabetes and Metabolism ,Receptor expression ,Population ,Gene Expression ,Pilot Projects ,Urotensin-II receptor, colon cancer, ulcerative colitis ,medicine.disease_cause ,Gastroenterology ,Inflammatory bowel disease ,Receptors, G-Protein-Coupled ,Western blot ,Internal medicine ,Internal Medicine ,medicine ,Humans ,Prospective Studies ,education ,Aged ,education.field_of_study ,Nutrition and Dietetics ,medicine.diagnostic_test ,business.industry ,Middle Aged ,Immune dysregulation ,medicine.disease ,Ulcerative colitis ,digestive system diseases ,Colitis, Ulcerative ,Female ,business - Abstract
BACKGROUND Urotensin II (U-II) is a vasoactive peptide that interacts with a specific receptor named UTR. Recently, our group has demonstrated increased UTR expression in both human colon adenocarcinoma cell lines and adenomatous polyps, as well as in colon carcinoma samples if compared to healthy colon samples of the same patients. We also showed that an UTR agonist induced an increase in colon adenocarcinoma cell growth in vitro, whereas the UTR block with a specific antagonist caused an inhibition of their growth and an inhibition of about 50% of both motility and cell invasion. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) associated with an increased baseline risk for colon cancer compared with the general population, and this risk is mostly attributed to chronic inflammation and immune dysregulation. This risk increases along with the duration of the disease, as demonstrated by many studies. There are no UTR expression data related to UC, and we therefore evaluated UTR expression in ill colon biopsies and in healthy colon ones of patients with UC and colon biopsies of healthy patients. METHODS We enrolled, prior to informed consent, 11 patients (5 males and 6 females, age range 29-75 years, median age 52 years) with first UC diagnosis compared to 11 healthy controls (6 males and 5 females, age range 30-78 years, median age 55 years). We have therefore sampled inflammatory and healthy tissue in UC patients. We have also taken colic tissue samples in healthy subjects. Evaluation of receptor expression was performed by reverse transcription-polymerase chain reaction (RT-PCR), Western Blot analysis. The ANOVA Test (P
- Published
- 2020